NeuroSense Therapeutics
NRSN
4 hedge funds and large institutions have $41.6K invested in NeuroSense Therapeutics in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0.33% less ownership
Funds ownership: 0.63% → 0.3% (-0.33%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
68% less capital invested
Capital invested by funds: $132K → $41.6K (-$90.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$57K |
| 2 |
Vanguard Personalized Indexing Management
Oakland,
California
|
-$8.49K |
NRSN Hedge Fund Activity: Q4 2022 in Review
4 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q4 2022, worth a combined $41.6K — down 68% from $132K a quarter earlier.
Fund positioning in NRSN was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $3.56K. The largest seller was Renaissance Technologies, cutting an estimated $57K.
- 4 institutional investors held NeuroSense Therapeutics (NRSN) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $41.6K of NeuroSense Therapeutics stock for Q4 2022, down 68% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics positions in Q4 2022 and 0 closed out.
- The largest NeuroSense Therapeutics buyer in Q4 2022 was UBS Group, an estimated $3.56K added.
- The largest NeuroSense Therapeutics seller in Q4 2022 was Renaissance Technologies, an estimated $57K sold.
Based on aggregated 13F filings for Q4 2022.